Hancock Jaffe Announces Endpoints for First-in-Human VenoValve Study

 

January 9, 2019—Hancock Jaffe Laboratories, Inc. (HJLI) announced endpoints for its upcoming VenoValve first-in-human study in Bogota, Colombia. The company recently received approval for the trial from INVIMA, the Colombian regulatory authority. The company is screening patients for the study, which will initially include 5 to 10 patients with severe chronic venous insufficiency.

Endpoints for the study will include improvements in reflux time, as well as three clinical measurements for venous disease: the revised Venous Clinical Severity Score (rVCSS), the Visual Analogue Scale (VAS), and the Venous Insufficiency Epidemiological and Economic Study (VEINES) instrument.

Follow-up will be conducted at 14, 30, 60, 90, and 180 days after implantations of the VenoValves. Duplex scans will be administered to measure reflux time in the deep venous system.

After completion of the 6-month study, the company will seek to present its data at international vascular conferences and publish the data in a peer-reviewed journal.

According to the company, the 90- and 180-day results will be of particular importance to the company and the FDA. HJLI will monitor patients for potentially serious adverse events related to the device. Knowledge gained from the Colombian study will be used to make any necessary design modifications to the VenoValves in preparation for the company’s United States pivotal trial.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.